May 27, 2015
EPAM Systems (NYSE:EPAM), a leading provider of software product development services, today announced that AccelEpi, a joint EPAM-UCB project, won the Bio-IT World Best Practices Award for Research and Drug Discovery. AccelEpi – Automated Accelerometric Detection of Epileptic Seizures in Rodents – is the first truly transformational technology platform that allows for a non-invasive, routine use of rodent models for research in drug discovery studies aiming at disease modification in epilepsy.
According to Dr. Rafal Kaminski, Head of Epilepsy at UCB, “The exceptional collaboration between UCB and EPAM Life Sciences resulted in an innovative discovery platform known as AccelEpi that accelerates the detection process of epileptic seizures in rodent experiments”. Dr. Kaminski explained that, “With such an innovative system, we may not only test drugs more quickly, but for the first time employ true disease models in antiepileptic drug discovery projects, which enables development of curative or disease-modifying therapies for patients with epilepsy”. In fact, as mentioned by Xavier Van Damme, the project leader, “AccelEpi is an excellent example of how multidisciplinary research involving signal analysis, software and IT infrastructure specialists working together with disease experts enables innovative drug discovery”.
“AccelEpi allows UCB to transition from measuring its drug candidates by their ability to fight induced seizures to proactively monitoring how those drug candidates reduce the rate of natural seizures in more true-to-life conditions,” said Richard Golob, Head of EPAM Life Sciences. “The platform is scaled to monitor up to 64 experimental animals in parallel, which enables running dose-response drug studies in real-time and significantly decreases the cost of experiments”.
Every year, Bio-IT World focuses attention on the critical role of IT in modern biomedical research and highlights platforms and strategies that can be shared across the industry to improve the quality, pace, and reach of science. “We are delighted once again to see such exceptional projects entered in this year’s competition,” said Allison Proffitt, editor of Bio-IT World. “The use of information technology has the potential to reinvigorate the life sciences in so many ways, and the winners of this year’s awards have shown creativity and initiative in applying these tools to problems large and small”.
EPAM Systems (NYSE:EPAM), a leading provider of software product development services, today announced that AccelEpi, a joint EPAM-UCB project, won the Bio-IT World Best Practices Award for Research and Drug Discovery. AccelEpi – Automated Accelerometric Detection of Epileptic Seizures in Rodents – is the first truly transformational technology platform that allows for a non-invasive, routine use of rodent models for research in drug discovery studies aiming at disease modification in epilepsy.
According to Dr. Rafal Kaminski, Head of Epilepsy at UCB, “The exceptional collaboration between UCB and EPAM Life Sciences resulted in an innovative discovery platform known as AccelEpi that accelerates the detection process of epileptic seizures in rodent experiments”. Dr. Kaminski explained that, “With such an innovative system, we may not only test drugs more quickly, but for the first time employ true disease models in antiepileptic drug discovery projects, which enables development of curative or disease-modifying therapies for patients with epilepsy”. In fact, as mentioned by Xavier Van Damme, the project leader, “AccelEpi is an excellent example of how multidisciplinary research involving signal analysis, software and IT infrastructure specialists working together with disease experts enables innovative drug discovery”.
“AccelEpi allows UCB to transition from measuring its drug candidates by their ability to fight induced seizures to proactively monitoring how those drug candidates reduce the rate of natural seizures in more true-to-life conditions,” said Richard Golob, Head of EPAM Life Sciences. “The platform is scaled to monitor up to 64 experimental animals in parallel, which enables running dose-response drug studies in real-time and significantly decreases the cost of experiments”.
Every year, Bio-IT World focuses attention on the critical role of IT in modern biomedical research and highlights platforms and strategies that can be shared across the industry to improve the quality, pace, and reach of science. “We are delighted once again to see such exceptional projects entered in this year’s competition,” said Allison Proffitt, editor of Bio-IT World. “The use of information technology has the potential to reinvigorate the life sciences in so many ways, and the winners of this year’s awards have shown creativity and initiative in applying these tools to problems large and small”.
Комментариев нет:
Отправить комментарий